(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
China Just Got Another Cheap EV America Would Love to Have - 2Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
- 3My Pioneering Excursion: Building a Startup
- 410 Energizing Vocations in the Innovation Business
- 5Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- Yemen's Houthis ready to join Iran war if needed, raising new shipping risk
- Fake new headlights rule steer Australian drivers astray
- Pick Your Favored kind of soup
- Figure out How to Adjust Your Handshake to Various Societies
- Pick Your #1 breakfast food
- Smoking rate among US adults drops to record low as vape use rises, CDC report finds
- Vote In favor of Your Number one Sort Of Blossoms
- Ten Awesome Authentic Realities That Will Leave You Interested
- New materials, old physics – the science behind how your winter jacket keeps you warm
